Add a listing
    Add a listing

    Cellularity

      Allogeneic placenta-derived stem cells

    General
    • Headquarters

      170 Park Avenue, Florham Park, NJ 07932, US

    • Founders & Team

      Robert Hariri, Peter Diamandis

    • Year Founded

      2017

    • Number of employees

      200

    • Company type

      Private company

    • Total funding ($M)

      290

    • Investors

      Bill Maris, Section 32, Human Longevity

    Technical Details
    • Aging Target

      Altered intercellular communication

    • Disease indication

      Crohn's disease

    • Product modality

      stem cells

    About

    Celularity, headquartered in Florham Park, N.J., is a clinical stage biotechnology company leading the next evolution in cellular medicine by delivering off-the-shelf allogeneic placenta-derived cellular therapies at unparalleled scale, quality and economics. Celularity’s innovative approach to cell therapy harnesses the unique therapeutic potential locked within the postpartum placenta. Through nature’s immunotherapy engine – the placenta – Celularity is leading the next evolution of cellular medicine with placenta-derived T cells, NK cells, and pluripotent stem cells to target unmet and underserved clinical needs in cancer, infectious and degenerative diseases.

    Categories

    How much is an extra decade of life worth to you? Make a bet on longevity science today.

    Donate to Impetus Grants

    You May Also Be Interested In